



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,897	05/19/2006	Breda Mary Cullen	101713-5057	6927
28977	7590	06/09/2010		
MORGAN, LEWIS & BOCKIUS LLP			EXAMINER	
1701 MARKET STREET			FUBARA, BLESSING M	
PHILADELPHIA, PA 19103-2921				
		ART UNIT	PAPER NUMBER	
		1618		
		MAIL DATE	DELIVERY MODE	
		06/09/2010	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/579,897

**Applicant(s)**

CULLEN ET AL.

**Examiner**

BLESSING M. FUBARA

**Art Unit**

1618

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 15 March 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) 5 and 9-13 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6-8 and 14-17 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/GS/US)  
Paper No(s)/Mail Date 5/19/06
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

1. CRF has been received and placed in the file. Response to the election requirement has also been received. Claims 8, 15 and 17 are amended. Claims 1-17 remain pending.

#### ***Election Requirement***

2. Applicant's election without traverse of claims 1-4, 6-8 and 14-17 in the reply filed on 3/15/2010 is acknowledged.

3. Claims 5 and 9-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim.

Election was made **without** traverse in the reply filed on 3/15/2010.

#### ***Specification***

4. Applicant has filed substitute specification. However has not pointed to sections of the specification that has been amended. Thus applicant is requested to point to the specification, preferably in the marked up version the pages and sections that have been amended.

#### ***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

6. Claims 1-4, 6-8 and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Cohen et al. (US 2002/0012693).
7. Cohen describes wound dressing comprising protease inhibitor such as elastase, support matrix such as carboxymethylated cellulose that medically acceptable, and the inhibitors are associated with the support matrix via covalent or ionic linkages (abstract, paragraph [0021] and [0022]). The tetra-peptide and di- or tri-peptide sequences (paragraphs [0023] and [0027]) and these sequences meet claim 8. The covalent or ionic linkages meet the limitation of the linker in claims 1-3 and 4. The carboxymethylated cellulose meets claim 4. Claim 6 recites what happens when the level of the enzyme is elevated and as such claim 6 is met. The peptide and the peptide sequences are the substrate for the protease so that claim 7 is met.
8. Claims 1-4, 6, 7 and 14-17 are rejected under 35 U.S.C. 102(a) as being anticipated by Cullen et al. (GB 2 382 775).
9. Cullen describes wound healing composition comprising polymer matrix that may be cross-linked hyaluronic gels, pain relieving substances or antimicrobial agents, antiseptics, protease inhibitors, proteases selected from elastase (see the whole document with emphasis on the abstract; pages 3 and 4; page 6, line 19 and claims 1-13). The antiseptics and the antimicrobials meet the limitation of therapeutic agent and claims 1, 6, 14, 15 are met. The protease inhibitor meets claims 1, the metalloproteinase (page 4, line 19) meet claim 16; claim 17 reads on the wound dressing of Cullen. The cross-linked polymer meets claims 2, 3 and because cross-linked hyaluronic acid is medically acceptable, claims 1-4 are met.
- 10.
11. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M. FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached on Monday to Thursday from 7 a.m. to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Blessing M. Fubara/  
Primary Examiner, Art Unit 1618